DK1095654T3 - Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose - Google Patents

Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose

Info

Publication number
DK1095654T3
DK1095654T3 DK01200197T DK01200197T DK1095654T3 DK 1095654 T3 DK1095654 T3 DK 1095654T3 DK 01200197 T DK01200197 T DK 01200197T DK 01200197 T DK01200197 T DK 01200197T DK 1095654 T3 DK1095654 T3 DK 1095654T3
Authority
DK
Denmark
Prior art keywords
medicament
raloxifene
atherosclerosis
analogues
manufacture
Prior art date
Application number
DK01200197T
Other languages
English (en)
Inventor
Steven Harold Zuckerman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1095654T3 publication Critical patent/DK1095654T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Lasers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Saccharide Compounds (AREA)
  • Finger-Pressure Massage (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01200197T 1993-12-21 1994-12-19 Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose DK1095654T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17060693A 1993-12-21 1993-12-21

Publications (1)

Publication Number Publication Date
DK1095654T3 true DK1095654T3 (da) 2004-03-15

Family

ID=22620568

Family Applications (2)

Application Number Title Priority Date Filing Date
DK94309461T DK0664121T3 (da) 1993-12-21 1994-12-19 Anvendelse af raloxifen og dets analoger til fremstilling af et medikament til behandling af aterosclerose og iskæmisk hjertesygdom
DK01200197T DK1095654T3 (da) 1993-12-21 1994-12-19 Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK94309461T DK0664121T3 (da) 1993-12-21 1994-12-19 Anvendelse af raloxifen og dets analoger til fremstilling af et medikament til behandling af aterosclerose og iskæmisk hjertesygdom

Country Status (20)

Country Link
EP (3) EP1095654B1 (da)
JP (1) JPH07196498A (da)
KR (1) KR950016722A (da)
CN (1) CN1095663C (da)
AT (3) ATE260104T1 (da)
AU (1) AU698389B2 (da)
CA (1) CA2138508A1 (da)
CZ (1) CZ286365B6 (da)
DE (3) DE69433578T2 (da)
DK (2) DK0664121T3 (da)
ES (3) ES2163425T3 (da)
HU (1) HUT71476A (da)
IL (1) IL112034A (da)
NO (1) NO313083B1 (da)
NZ (1) NZ270162A (da)
PT (3) PT1095654E (da)
RU (1) RU2127592C1 (da)
TW (1) TW427902B (da)
UA (1) UA39941C2 (da)
ZA (1) ZA9410091B (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
DE69622472T2 (de) * 1995-06-07 2003-02-06 Eli Lilly And Co., Indianapolis Behandlung von Krankheiten durch Induktion von BEF-1 Transkriptionsfaktor
US6545027B1 (en) 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
AU6277396A (en) 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
WO2000010606A1 (fr) 1998-08-24 2000-03-02 Kurokawa, Kiyoshi Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux
RU2464794C1 (ru) * 2011-10-25 2012-10-27 Канапья Табылдыевич Шагиев Состав для производства кисломолочного продукта "курт"
CN103768601A (zh) * 2012-10-22 2014-05-07 中国科学院上海生命科学研究院 抑制micro-RNA155用于预防和治疗动脉粥样硬化的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) * 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol

Also Published As

Publication number Publication date
ES2163425T3 (es) 2002-02-01
RU94045270A (ru) 1996-10-20
DK0664121T3 (da) 2001-12-03
NO944913D0 (no) 1994-12-19
CN1095663C (zh) 2002-12-11
ES2210089T3 (es) 2004-07-01
EP1095654A3 (en) 2001-06-13
EP0963756B1 (en) 2004-02-25
RU2127592C1 (ru) 1999-03-20
DE69433348T2 (de) 2004-08-26
EP0963756A2 (en) 1999-12-15
JPH07196498A (ja) 1995-08-01
DE69433578T2 (de) 2004-12-16
CN1108090A (zh) 1995-09-13
PT963756E (pt) 2004-06-30
ATE254459T1 (de) 2003-12-15
ATE260104T1 (de) 2004-03-15
ZA9410091B (en) 1996-06-19
AU698389B2 (en) 1998-10-29
CA2138508A1 (en) 1995-06-22
CZ320494A3 (en) 1995-09-13
NZ270162A (en) 1997-06-24
PT1095654E (pt) 2004-04-30
DE69428882D1 (de) 2001-12-06
EP1095654A2 (en) 2001-05-02
IL112034A (en) 1999-03-12
EP0664121B1 (en) 2001-10-31
DE69433348D1 (de) 2003-12-24
EP0664121A1 (en) 1995-07-26
EP0963756A3 (en) 1999-12-22
DE69433578D1 (de) 2004-04-01
CZ286365B6 (cs) 2000-03-15
ATE207749T1 (de) 2001-11-15
IL112034A0 (en) 1995-03-15
KR950016722A (ko) 1995-07-20
NO313083B1 (no) 2002-08-12
TW427902B (en) 2001-04-01
HUT71476A (en) 1995-11-28
AU8156394A (en) 1995-06-29
DE69428882T2 (de) 2002-04-25
ES2215270T3 (es) 2004-10-01
NO944913L (no) 1995-06-22
HU9403660D0 (en) 1995-02-28
EP1095654B1 (en) 2003-11-19
UA39941C2 (uk) 2001-07-16
PT664121E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
DK1095654T3 (da) Anvendelse af raloxifen og dens analoger til fremstilling af et medikament til inhibering af LDL-oxidation og aterosklerose
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
ES2157957T3 (es) Procedimientos para inhibir la endometriosis.
DK0651999T3 (da) Fremgangsmåder til inhibering af livmoderfibrose
DK0659416T3 (da) Inhibering af seborE og acne
DK0652002T3 (da) Anvendelse af 2-phenyl-3-aroylebenzothiophener til fremstilling af et medikament til hæmning af brusknedbrydning
DK0652004T3 (da) Fremgangsmåder til behandling af resistente neoplasmer
NO944923L (no) Hemming av vektökning eller indusering av vekttap
NO20000750D0 (no) Fremgangsmåte for å redusere blodplatetall
GR3002594T3 (en) Aromatic thioethers
DK0771201T3 (da) Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi